Bladder Cancer, Melanoma, NSCLC, Renal Cell Carcinoma
Conditions
Brief summary
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-135 (JSC BIOCAD, Russia) in Patients with Advanced Solid Tumors
Interventions
DRUGBCD-135
Monoclonal anti-PD-L1 antibody
Sponsors
Biocad
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient provides a written informed consent and is able to follow the requirements of the Protocol; 2. Age ≥ 18 years 3. Histologically confirmed cancer (well-documented test results; preferably, block specimens available): * Unresectable (stage III/IV) or metastatic (stage IV) melanoma (the drug will be used as the first or subsequent therapy lines); * Locally advanced or metastatic EGFR/ALK wt NSCLC (squamous cell carcinoma/adenocarcinoma), progressive after the first-line therapy with platinum-based CT or EGFR/ALK wt NSCLC progressive after the first-line therapy with EGFR/ALK inhibitors (the drug will be used as a second therapy line); * Metastatic clear cell renal carcinoma, progressive after at least the first-line therapy (the drug will be used as a second or third therapy lines); * Locally advanced or metastatic bladder cancer progressive on/after therapy with platinum-based CT (the drug will be used as a second therapy line); 4. ECOG score of 0 to 1; 5. Presence of blocks for histological examination and/or patient's agreement to conduct a biopsy of an accessible lesions to obtain a histological material for examination of PD-L1 status 6. Measurable disease (at least one lesion) according to RECISTv.1.1; 7. Resolved toxicity events from the previous therapy or adverse consequences of surgical interventions to ≤ grade 1 CTCAE v. 4.03, except for chronic/irreversible adverse events not affecting the safety of the study therapy (e.g. alopecia); 8. No severe pathology of organs or systems; 9. Life expectancy of at least 12 weeks from the screening; 10. Patients of childbearing potential enrolled in the study must agree to use reliable contraception methods throughout the study period, beginning 2 weeks before the inclusion in the study and up to 8 weeks after the last dose of BCD-100.
Exclusion criteria
1. Severe concomitant illnesses or life-threatening consequences (including pleural/pericardial/peritoneal effusion that requires medical intervention, pulmonary lymphangitis, or involvement of \>50% renal parenchyma); 2. Brain metastases, progressive or associated with clinical symptoms (e.g. cerebral edema or spinal cord compression). Exclusions: metastases that do not progress and do not require steroids and/or anticonvulsants within at least 4 weeks before randomization; 3. Severe cardiovascular disorders within 6 months before screening; 4. Autoimmune diseases; 5. Conditions requiring steroids or any other immunosuppressants; 6. Blood disorders: ANC ≤1,500/mm3; platelets ≤100,000/mm3; or Hb ≤90 g/L; 7. Renal function impairment: creatinine ≥1.5 × ULN; 8. Hepatic function impairment: bilirubin ≥1.5 × ULN; AST and ALT ≥2.5 × ULN (5 × ULN for patients with liver metastases), AlkPh ≥ 5 × ULN; 9. LDH level \>2 ULN; 10. Prior anticancer treatment within 28 days before starting the study drug (surgery, radiation therapy, targeted therapy, immunotherapy, vaccine treatment or chemotherapy); 11. More than * 2 therapy lines of unresectable/metastatic melanoma, * 1 therapy line of metastatic NSCLC, * 2 therapy lines of metastatic RCC; * 1 therapy line of metastatic BC; 12. Prior treatment with anti-PD1/PDL1 agents or CTLA4 inhibitors; 13. Concurrent malignancy except for radically resected cervical carcinoma in situ or radically resected basal cell/squamous cell carcinoma; 14. Conditions limiting patient's ability to follow the Protocol requirements (dementia, neurological or psychiatric disorders, drug or alcohol abuse, etc.); 15. Simultaneous participation in any other clinical trial; participation in other clinical trials within 28 days before inclusion in the present study; previous participation in the present study. 16. Acute infections or active chronic infections; 17. Documented HIV infection; 18. Positive screening results for Hbs-antigen, hepatitis B core antibodies (anti-HBc Ab) and/or hepatitis C antibodies; 19. Positive results of microprecipitation reaction together with positive TPHA assay results at the screening; 20. Body weight \> 100 kg. 21. Intravenous administration of the drug is impossible; 22. Intravenous administration of contrast agents is impossible; 23. Hypersensitivity to any component of BCD-100. 24. Known history of hypersensitivity to monoclonal antibodies; 25. Pregnancy or breastfeeding;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DCR | 85 days | Disease control rate (CR+PR+SD). Pilot efficacy assessment is not the primary objective of this study and will be conducted by surrogate endpoints describing the direct antitumor effect of the drug. |
Countries
Russia
Contacts
Primary ContactMariia Shustova, MD
Outcome results
None listed